Kazia Therapeutics Leverages CRO Strategy to Advance SETDB1 Oncology Program

• Kazia Therapeutics plans to advance its SETDB1 inhibitor program alongside its PD-L1 degrader platform using shared CRO resources.

• The company expects coordinated study design and scientific collaborations to improve execution efficiency and accelerate IND-enabling studies.

Kazia Therapeutics Limited announced plans to advance its newly in-licensed SETDB1 oncology program in parallel with its PD-L1 degrader platform, leveraging shared contract research organization (CRO) resources to support development. The company said the coordinated approach is intended to improve execution efficiency as both programs move toward IND-enabling studies.

The strategy involves shared CRO partnerships, coordinated study design, and existing scientific collaborations across both development programs. According to the company, this integrated model is expected to streamline operational execution and accelerate preclinical development timelines.

Kazia indicated that advancing multiple oncology programs through shared CRO infrastructure allows for more efficient resource utilization while maintaining development momentum across its pipeline. The approach also supports parallel experimentation and data generation, which may help inform clinical strategy decisions earlier in development.

The SETDB1 program, recently in-licensed from QIMR Berghofer, targets tumor immune resistance mechanisms through epigenetic modulation. The initiative complements Kazia’s existing oncology assets, including its PD-L1 degrader platform, creating a multi-program development strategy supported by CRO collaborations.

“By leveraging shared CRO resources, coordinated study design, and established scientific collaborations, the Company expects to achieve meaningful execution efficiencies.”

Kazia Official Statement